Pfizer Launches New Antibiotic Zavicefta in UK and Germany

As response to the urgent need for new antibiotics in the increasing threat of antimicrobial resistance, Pfizer has launched a new drug for multidrug resistant (MDR) infections.

‘The European Medicines Agency (EMA) cleared Zavicefta (ceftazidime and avibactam) for the treatment of complicated Gram-negative bacterial infections requiring hospitalisation last year. The drug was originally developed by AstraZeneca (AZ) but sold to Pfizer last year in a $1.58bn deal.

Specifically, Zavicefta is approved in the EU for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired pneumonia (HAP), but can also be used in the treatment of other serious Gram-negative infections in adults with limited treatment options.’

Source: PMLiVE

Read the entire article here.

Read the Pfizer press release here.